

## Special Issue

# Estrogen for the Treatment and Prevention of Breast Cancer

### Message from the Guest Editor

Estrogen exerts a significant influence on the development of breast cancer, primarily by binding to cellular estrogen receptors (ERs). Breast cancer can be categorized into two subtypes on the basis of the presence of ERs: ER-positive and ER-negative. In hormone receptor-positive (HR+) breast cancer, ERs serve as the principal transcription factors driving oncogenesis and play dual roles as both predictor and target of antiestrogen therapy response. In the case of ER-negative breast cancer, a combination of chemotherapy and molecular-targeted drugs is commonly employed, with potential effectiveness anticipated through immune checkpoint inhibitors. Additionally, hormone therapies may prove efficacious in instances where other hormone receptors such as androgen and glucocorticoid receptors are expressed in ER-negative breast cancer. The involvement of germline BRCA1/2 mutations in both ER-negative and ER-positive breast cancer pathogenesis is well established; however, numerous unknown factors persist regarding the pathological characteristics, genetic background, and immunological features associated with ER-negative breast cancer.

---

### Guest Editor

Prof. Dr. Virgil Craig Jordan  
Department of Breast Medical Oncology, MD Anderson Cancer Center,  
University of Texas, 1515 Holcombe Blvd., Unit 1354, Houston, TX  
77030, USA

---

### Deadline for manuscript submissions

closed (30 April 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/190699](https://mdpi.com/si/190699)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).